EF 40

Drug Profile

EF 40

Latest Information Update: 04 Jul 2000

Price : $50

At a glance

  • Originator Scotia Holdings [CEASED]
  • Class Calcium regulators; Osteoporosis therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Jul 2000 Discontinued-II for Postmenopausal osteoporosis in United Kingdom (PO)
  • 09 Oct 1997 Phase-II clinical trials for Postmenopausal osteoporosis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top